Drug intelligence / Profile preview

zeluvalimab

Development stage: Phase 1
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

Zeluvalimab (formerly known as AMG 404) is a human monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on immune cells. By binding to PD-1 and blocking its interaction with its ligands PD-L1 and PD-L2, zeluvalimab acts as an immune checkpoint inhibitor. This mechanism enhances anti-tumor immunity by preventing tumors from suppressing immune responses via the PD-1 pathway. Zeluvalimab is being developed primarily for the treatment of advanced solid tumors and has also been studied in prostate cancer[1][2][4][5][7].

Other names: zeluvalimabAMG 404AMG404AMG-40420C1.009

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on zeluvalimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zeluvalimab.

Explore the full profile